Vanderbilt Clinical Trials

Patient Inclusion: - Patient may have M0 or M1 disease - Confirmed diagnosis of CRPC defined by both Testosterone at castrate levels, as evidenced by a serum testosterone level ≤ 1.73 nmol/L (50 ng/dL) and Clear progressive disease, as evidenced by a minimum of two rising PSA levels measured at least 7 days apart or new clinical or imaging evidence of progressive metastatic disease - Initiating the first or second line treatment for CRPC: including anti- androgens, androgen synthesis inhibitors, chemotherapy, immunotherapy or radionuclide therapy. Previous first line CRPC treatments are limited to: First generation anti-androgens (bicalutamide, flutamide, or nilutamide) or Sipuleucel-T - Patients may be enrolled within 90 days from the time of decision to treat or within 90 days of treatment initiation. - Willing and able to complete periodic patient-reported outcome (PRO) questionnaires, with or without assistance - Estimated life expectancy of ≥ 6 months Caregiver Inclusion: - Meets the definition of an unpaid relative or friend who helps the patient with his or her activities of daily living - Willing and able to complete caregiver-reported outcome questionnaires over the course of the patient's participation in the study

Patient Exclusion: - Receiving concomitant treatment for other cancer (excluding basal cell carcinoma, squamous cell carcinoma and treatment for hormone sensitive prostate cancer) within 6 months prior to enrollment.